Company History
(History04 2014-)

History 04

2014 -

<

To be a manufacturer highly regarded by the world’s healthcare community

  • 2016

    Launched Pulmonary Arterial Hypertension agent Uptravi® in the US. Since then, launched in Europe and other countries.

    Completed construction of Active Pharmaceutical Ingredient Manufacturing Building in the headquarter areas

    Received the Minister of State for Special Missions Award for "Nippon Shinyaku children's literary awards "children's literary awards

  • 2017

    Completed construction of manufacturing facility for highly active solid formulations in Odawara Central Factory

  • 2018

    Introduced industry-first "MR flextime system" as part of work style reform

    Presented the results of clinical trials for viltolarsen, a treatment for Duchenne muscular dystrophy (DMD), conducted in Japan and the U.S. at academic conferences held in New Orleans, the U.S., and Mendoza, Argentina

    Launched CD20-positive follicular lymphoma agent GAZYVA®

    Started a phased process of applying for approval for the marketing of viltolarsen, a DMD treatment, in the U.S.

  • 2019

    Launched sinusoidal obstruction syndrome (hepatic veno-occlusive disease) agent Defitelio®

    Nippon Shinyaku Co., Ltd. celebrated the centenary of its establishment on October 1

  • 2020

    Signed the United Nations Global Compact (UNGC) and joined the Global Compact Network Japan(GCNJ)

    Launched Duchenne Muscular Dystrophy agent VILTEPSO® in Japan

    Launched Duchenne Muscular Dystrophy agent VILTEPSO injection in U.S.

  • 2021

    Established a local subsidiary “Beijing Nippon Shinyaku Co., Ltd.” in Beijing, China

    Established a local subsidiary “Tianjin Nippon Shinyaku Co., Ltd.” in Tianjin, China

  • 2022

    Selected as a Constituent of the FTSE Blossom Japan Sector Relative Index

    Launched Seizures Associated with Dravet syndrome agent Fintepla®

  • 2023

    Launched iron deficiency anemia agent MonoVer®

    Launched High-risk acute myeloid leukemia agent Vyxeos®